Spago Nanomedical Crecimiento futuro

Future controles de criterios 6/6

Spago Nanomedical se prevé un crecimiento anual de los beneficios y los ingresos de 65.7% y 43.5% respectivamente. Se prevé que el BPA sea de grow en 54.9% al año. Se prevé que la rentabilidad de los fondos propios sea de 128% en 3 años.

Información clave

56.0%

Tasa de crecimiento de los beneficios

62.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	36.7%
Tasa de crecimiento de los ingresos	50.6%
Rentabilidad financiera futura	128.0%
Cobertura de analistas	Low
Última actualización	08 Feb 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We're Not Worried About Spago Nanomedical's (STO:SPAGO) Cash Burn

Sep 21

We're Interested To See How Spago Nanomedical (STO:SPAGO) Uses Its Cash Hoard To Grow

May 26

Loss-Making Spago Nanomedical AB (publ) (STO:SPAG) Set To Breakeven

Mar 30

We're Hopeful That Spago Nanomedical (NGM:SPAG) Will Use Its Cash Wisely

Feb 03

Loss-Making Spago Nanomedical AB (publ) (NGM:SPAG) Expected To Breakeven In The Medium-Term

Dec 11

Previsiones de crecimiento de beneficios e ingresos

OM:SPAGO - Estimaciones futuras de los analistas y datos financieros pasados (SEK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	111	46	45	46	2
12/31/2025	14	-51	-51	-51	1
12/31/2024	29	-33	-32	-31	1
12/31/2023	6	-42	-45	-45	N/A
9/30/2023	9	-41	-44	-40	N/A
6/30/2023	9	-42	-50	-45	N/A
3/31/2023	8	-44	-48	-43	N/A
12/31/2022	6	-39	-42	-38	N/A
9/30/2022	6	-39	-47	-43	N/A
6/30/2022	6	-41	-47	-43	N/A
3/31/2022	6	-43	-44	-40	N/A
12/31/2021	6	-39	-40	-36	N/A
9/30/2021	7	-32	-35	-29	N/A
6/30/2021	7	-27	-29	-23	N/A
3/31/2021	7	-20	-28	-22	N/A
12/31/2020	7	-19	-25	-19	N/A
9/30/2020	7	-20	-40	-22	N/A
6/30/2020	13	-21	-33	-21	N/A
3/31/2020	16	-21	-37	-23	N/A
12/31/2019	19	-20	-40	-21	N/A
9/30/2019	25	-18	-45	-16	N/A
6/30/2019	25	-15	-40	-16	N/A
3/31/2019	27	-13	-44	-10	N/A
12/31/2018	30	-11	-39	-11	N/A
9/30/2018	30	-11	-19	-10	N/A
6/30/2018	27	-10	-34	-7	N/A
3/31/2018	23	-10	-24	-9	N/A
12/31/2017	18	-9	-26	-8	N/A
9/30/2017	13	-8	N/A	-7	N/A
6/30/2017	12	-8	N/A	-7	N/A
3/31/2017	11	-7	N/A	-7	N/A
12/31/2016	11	-8	N/A	-8	N/A
9/30/2016	9	-7	N/A	-7	N/A
6/30/2016	8	-7	N/A	-6	N/A
3/31/2016	8	-7	N/A	-7	N/A
12/31/2015	8	-7	N/A	-5	N/A
9/30/2015	7	-8	N/A	-7	N/A
6/30/2015	7	-7	N/A	-8	N/A
3/31/2015	7	-7	N/A	-7	N/A
12/31/2014	8	-6	N/A	-6	N/A
9/30/2014	7	-7	N/A	-6	N/A
6/30/2014	9	-7	N/A	-5	N/A
3/31/2014	8	-5	N/A	-3	N/A
12/31/2013	8	-5	N/A	-8	N/A
9/30/2013	10	-4	N/A	-3	N/A
6/30/2013	9	-4	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: SPAGO se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (0.9%).

Beneficios vs. Mercado: SPAGO se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: SPAGO se espera que sea rentable en los próximos 3 años.

Ingresos vs. Mercado: SPAGOSe prevé que los ingresos de la empresa (43.5% al año) crezcan más deprisa que los del mercado Swedish (1% al año).

Ingresos de alto crecimiento: SPAGOSe prevé que los ingresos de la empresa (43.5% al año) crezcan más deprisa que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: SPAGOSe prevé que la Rentabilidad de los fondos propios de la empresa sea muy elevada dentro de 3 años (76.3%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Spago Nanomedical Crecimiento futuro

Future controles de criterios 6/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 35% to kr0.93

No longer forecast to breakeven

Consensus EPS estimates upgraded to kr0.20 loss

Forecast to breakeven in 2023

Price target decreased to kr9.50

Consensus forecasts updated

Recent updates

Spago Nanomedical AB (publ) Announces Appointment of Birgitta Rembratt Svensson as Head of CMC & Supply, Effective June 1, 2024

Price target decreased by 35% to kr0.93

Full year 2023 earnings released: kr0.43 loss per share (vs kr0.61 loss in FY 2022)

Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01

New major risk - Shareholder dilution

Spago Nanomedical Announces Positive Top Line Data from a Clinical Phase IIa Study in Patients with Endometriosis

Spago Nanomedical Reports Positive Top Line Data from Clinical Phase IIa Study SPAGOPIX-02 in Patients with Endometriosis

Spago Nanomedical AB (publ) Announces First Patient Dosed in Spago Nanomedical's Clinical Phase I/IIA Study Within the Tumorad(R) Program

Third quarter 2023 earnings released

Spago Nanomedical AB (publ) Announces Publication of Four New Patent Applications Filed with the European Patent Office

Spago Nanomedical Announces Cancer Therapy Approved for Phase I/IIa

Spago Nanomedical AB (publ) Receives Approval to Initiate the Clinical Phase I/IIa Study with Tumorad in Australia

New minor risk - Profitability

No longer forecast to breakeven

Consensus EPS estimates upgraded to kr0.20 loss

Second quarter 2023 earnings released

Spago Nanomedical Updates on the Clinical Phase IIa Study SPAGOPIX-02

Spago Nanomedical AB (Publ) Announces Establishment of A Scientific Advisory Board

High number of new and inexperienced directors

Spago Nanomedical AB (publ) Submits Application to Start Tumorad(R) Clinical Phase I/IIa Study

First quarter 2023 earnings released: kr0.16 loss per share (vs kr0.24 loss in 1Q 2022)

Spago Nanomedical AB (Publ) Elects New Directors

Full year 2022 earnings released: kr0.61 loss per share (vs kr0.99 loss in FY 2021)

Spago Nanomedical AB (Publ) Publishes Scientific Paper on Positive Preclinical Data with Tumorad(R) as Treatment of Solid Tumors

First Patient Dosed in Spago Nanomedical’S Endometriosis Phase Iia Clinical Study

Spago Nanomedical Initiates Clinical Trial with Spagopix in Endometriosis and Concludes SpagoPix -01

Forecast to breakeven in 2023

Price target decreased to kr9.50

Spago Nanomedical Gets SpagoPix Abstract Accepted At Breast Cancer Conference

Spago Nanomedical Announces Process of Entering Clinical Phase with Its Drug Candidate [177]Lu-SN201

Second quarter 2022 earnings released

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast breakeven date pushed back to 2023

Spago Nanomedical AB (publ), Annual General Meeting, May 18, 2022

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS and revenues miss analyst expectations

Spago Nanomedical AB (publ) Announces New Results

Spago Nanomedical Announces Positive Interim Results from Phase I Study with SpagoPix

Spago Nanomedical AB (Publ) Announces Interim Results from the Second Dose Group in Ongoing Clinical Phase I Study SPAGOPIX-01

Spago Nanomedical AB (Publ) Announces That Second Dose Group Fully Recruited in Spago Nanomedical's Phase 1 Study with Spagopix

Third quarter 2021 earnings released

We're Not Worried About Spago Nanomedical's (STO:SPAGO) Cash Burn

Second quarter 2021 earnings released

We're Interested To See How Spago Nanomedical (STO:SPAGO) Uses Its Cash Hoard To Grow

Full year 2020 earnings released: kr0.70 loss per share (vs kr1.01 loss in FY 2019)

Loss-Making Spago Nanomedical AB (publ) (STO:SPAG) Set To Breakeven

Revenue beats expectations, earnings disappoint

Full year 2020 earnings released: kr0.60 loss per share (vs kr1.01 loss in FY 2019)

We're Hopeful That Spago Nanomedical (NGM:SPAG) Will Use Its Cash Wisely

New 90-day high: kr9.14

New 90-day high: kr8.78

Loss-Making Spago Nanomedical AB (publ) (NGM:SPAG) Expected To Breakeven In The Medium-Term

New 90-day high: kr8.08

New 90-day low: kr5.40

New 90-day low: kr6.22

An undisclosed buyer acquired 7.8% stake in Spago Nanomedical AB (publ) (NGM:SPAG) from HealthInvest Partners AB.

Earnings released

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento